RudaCure was selected for the 2021 Bio-Medical Technology Development Project (Principal Investigator: Yuseung Ha) for its 全球拓展 initiative. Through this project, the company will receive support until July of the same year for foundational research on establishing an overseas subsidiary and business collaboration for 美国 临床试验 of the 眼科 滴眼液 RCI001.
In the project evaluation, the company was recognized for its excellent 研发 and commercialization progress and analysis, as well as its clear global 初创企业 goals. The company was selected by recognizing the marketability and future potential of RCI001 in a world where no fundamental treatment drug for 干眼症 currently exists.
This project will select 5 companies through a first-round evaluation and provide annual support of KRW 300 million per year for 3 years for 全球拓展 activities.